Istradefylline

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Istradefylline
Istradefylline.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.230.117
Chemical and physical data
Formula C20H24N4O4
Molar mass 384.429 g/mol
3D model (Jmol)
  (verify)

Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson's disease.[1] Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.

References[edit]

  1. ^ Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD (2008). "Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)". Annals of Neurology. 63 (3): 295–302. PMID 18306243. doi:10.1002/ana.21315.